secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vericel Corp (VCEL)
CIK:        0000887359
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001140361-26-001060
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vericel prelim 2025 revenue $276M (+23% Q4); MACI rev $239.5M; GAAP net profitable 2nd year
--------------------------------------------------------------------------------

- Total revenue ~$276M; MACI $239.5M (+20%+ YoY 3rd consecutive yr); Burn Care $36.5M.
- Gross margin 74%; adj. EBITDA margin 26%; $200M cash & investments, no debt.
- Q4 set records for MACI implants, implanting surgeons, biopsies; >900 MACI Arthro trained surgeons.
- Completed sales force expansion; initiated MACI Ankle MASCOT trial; new mfg facility on track for 2026.
- CEO cites strong execution, expects continued high revenue growth and profitability improvement in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887359/000114036126001060/0001140361-26-001060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887359/000114036126001060/ef20062769_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-001060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer